Denali Therapeutics Inc.

DNLI

NASDAQ

Healthcare

Biotechnology

South San Francisco, CA, US443 employeesdenalitherapeutics.com

$20.61

+0.93(4.73%)

Mkt Cap $3.3B

$11.47

$22.74

52-Week Range

At a Glance

AI-generated

Revenue breakdown: ATV Abeta Option Material Right (84.5%), CNS Product (9.4%), Peripheral Product (5.1%).

8-K

Denali Therapeutics regains full rights to DNL593 after Takeda terminates their collaboration agreement for strategic reasons, with Phase 1/2 data expected by end of 2026.

$3.3B

Market Cap

—

Revenue

-$463M

Net Income

Employees443

Fundamentals

How The Business Makes Money

Revenue by Segment

ATV Abeta Option Material Right84.5%($583M)

CNS Product9.4%($65M)

Peripheral Product5.1%($35M)

Option Fee Payment0.7%($5M)

Option Services0.2%($2M)

Activity

What Changed Recently

Material Agreement

Apr 2, 2026

Termination of a Material Definitive Agreement. On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company

Financing

Mar 30, 2026

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in Item 1.01 of the

Financial Results

Feb 25, 2026

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shal

Regulation FD

Mar 24, 2026

by reference. The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of

Regulation FD

Jan 5, 2026

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc

Peer Companies

Company	Price	Change	Market Cap	P/E
IBRXImmunityBio, Inc.	$7.30	+2.31%	$7.5B	-26.5
COGTCogent Biosciences, Inc.	$35.31	+0.21%	$5.7B	-7.3
LQDALiquidia Corporation	$37.63	+0.43%	$3.3B	-44.9
BEAMBeam Therapeutics Inc.	$24.65	+1.78%	$2.5B	-32.4
RCUSArcus Biosciences, Inc.	$22.95	+5.06%	$2.3B	-6.5
ETNBETNB	$14.84	+0.00%	$2.2B	—
AGIOAgios Pharmaceuticals, In...	$35.17	+2.87%	$2.1B	-4.0
GLPGGalapagos N.V.	$29.40	-1.22%	$1.9B	5.6

Analyst View

Company Profile

CIK0001714899

ISINUS24823R1059

CUSIP24823R105

Phone650 866 8548

Address161 Oyster Point Boulevard, South San Francisco, CA, 94080, US

SEC EDGAR